50-76-0

ARC Monographs on the Evaluation of Carcinogenic Risk of Chemicals to Man . 7 (1987),p. 80.(World Health Organization, Internation Agency for Research on Cancer,Lyon, France.: ) (Single copies can be ordered from WHO Publications Centre U.S.A., 49 Sheridan Avenue, Albany, NY 12210) ; NCI Carcinogenesis Studies (ipr); No Evidence: mouse RRCRBU    Recent Results in Cancer Research. 52 (1975),1.

The Actinomycin D with the cas number 50-76-0. It is also called 2-amino-4,6-dimethyl-3-oxo-1-N,9-N-bis[7,11,14-trimethyl-2,5,9,12,15-pentaoxo-3,10-di(propan-2-yl)-8-oxa-1,4,11,14-tetrazabicyclo[14.3.0]nonadecan-6-yl]phenoxazine-1,9-dicarboxamide name by IUPAC. It seems like bright red rhomboid prisms or red powder. It belongs to the flollowing product categories: (1)Antibiotics; (2)Antibiotic Explorer; (3)Intermediates & Fine Chemicals; (4)Peptides; (5)Pharmaceuticals; (6)Caspases/Apoptosis. Actinomycin D is stable, but light sensitive, especially in dilute solution. And it is incompatible with strong acids, strong bases, strong oxidizing agents. Besides, it is quite combustible. It is should be stored at 2-8°C.

Properties of Actinomycin D are: (1)ACD/LogP: -0.33 ; (2)# of Rule of 5 Violations: 0 ; (3)ACD/LogD (pH 5.5): -2.83 ; (4)ACD/LogD (pH 7.4): -2.83 ; (5)ACD/BCF (pH 5.5): 1 ; (6)ACD/BCF (pH 7.4): 1 ; (7)ACD/KOC (pH 5.5): 1 ; (8)ACD/KOC (pH 7.4): 1 ; (9)#H bond acceptors: 3 ; (10)#H bond donors: 3 ; (11)#Freely Rotating Bonds: 2 ; (12)Polar Surface Area: 29.54Ų ; (13)Index of Refraction: 1.464 ; (14)Molar Refractivity: 25.64 cm³ ; (15)Molar Volume: 92.9 cm³ ; (16)Polarizability: 10.16 ×10^-24cm³ ; (17)Surface Tension: 42.4 dyne/cm ; (18)Density: 1.109 g/cm³ ; (19)Flash Point: 77.4 °C ; (20)Enthalpy of Vaporization: 48.56 kJ/mol ; (21)Boiling Point: 204.4 °C at 760 mmHg ; (22)Vapour Pressure: 0.108 mmHg at 25°C

Uses of Actinomycin D: Actinomycin D is mainly used as an investigative tool in cell biology to inhibit transcription. Besides, Actinomycin D is one chemotherapy drug which has a long history, and has been used in therapy for many years. In additon, it is also used intravenously in treatment of a variety of cancers including gestational trophoblastic neoplasia, Wilms' tumor and rhabdomyosarcoma and so on.

When you are using Actinomycin D, please be cautious about it as the following: It is quite irritating to eyes, respiratory system and skin. When you are using this chemical, please wear suitable gloves and eye/face protection to avoid contact with skin and eyes. In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. Besides, it is very toxic by inhalation, in contact with skin and if swallowed. For instance, it may cause harm to the unborn child and may cause cancer, tough with limited evidence of a carcinogenic effect. Hence, in order not to breathe dust, you would better keep it locked up, and avoid exposure - obtain special instructions before use. After contact with skin, wash immediately with plenty of soap-suds.

You can still convert the following datas into molecular structure :
1.SMILES:O=C(O)C(N)(C)C
2.InChI:InChI=1/C4H9NO2/c1-4(2,5)3(6)7/h5H2,1-2H3,(H,6,7)

Toxic information of Actinomycin D can be showed as follows:

Organism	Test Type	Route	Reported Dose (Normalized Dose)	Effect	Source
bird - wild	LD50	oral	1mg/kg (1mg/kg)		Archives of Environmental Contamination and Toxicology. Vol. 12, Pg. 355, 1983.
cat	LDLo	intraperitoneal	75ug/kg (0.075mg/kg)	BEHAVIORAL: SOMNOLENCE (GENERAL DEPRESSED ACTIVITY) GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA"	Antibiotiki. Vol. 16, Pg. 443, 1971.
dog	LDLo	intravenous	160ug/kg (0.16mg/kg)	GASTROINTESTINAL: NAUSEA OR VOMITING BLOOD: LEUKOPENIA	National Technical Information Service. Vol. PB225-594,
guinea pig	LD50	unreported	330ug/kg (0.33mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
hamster	LD50	unreported	600ug/kg (0.6mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
human	TDLo	intravenous	40ug/kg/4D-I (0.04mg/kg)	SKIN AND APPENDAGES (SKIN): "DERMATITIS, OTHER: AFTER SYSTEMIC EXPOSURE"	New England Journal of Medicine. Vol. 281, Pg. 1094, 1969.
mouse	LD50	intraperitoneal	750ug/kg (0.75mg/kg)	BLOOD: CHANGES IN BONE MARROW NOT INCLUDED ABOVE IMMUNOLOGICAL INCLUDING ALLERGIC: DECREASED IMMUNE RESPONSE	Cancer Treatment Reports. Vol. 61, Pg. 103, 1977.
mouse	LD50	intravenous	1025ug/kg (1.025mg/kg)		Antibiotiki. Vol. 16, Pg. 443, 1971.
mouse	LD50	oral	13mg/kg (13mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES	Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
mouse	LD50	subcutaneous	500ug/kg (0.5mg/kg)		"Antibiotics: Origin, Nature, and Properties," Korzyoski, T., et al., eds., Washington, DC, American Soc. for Microbiology, 1978Vol. 2, Pg. 1268, 1978.
mouse	LDLo	intratracheal	1mg/kg (1mg/kg)		Toxicology Letters. Vol. 30, Pg. 63, 1986.
rabbit	LD50	unreported	150ug/kg (0.15mg/kg)		Arzneimittel-Forschung. Drug Research. Vol. 30, Pg. 236, 1980.
rat	LD50	intraperitoneal	100ug/kg (0.1mg/kg)		Acta Obstetrica et Gynaecologica Japonica, English Edition. Vol. 23, Pg. 219, 1976.
rat	LD50	intravenous	460ug/kg (0.46mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES	Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rat	LD50	oral	7200ug/kg (7.2mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES	Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.
rat	LD50	subcutaneous	800ug/kg (0.8mg/kg)	GASTROINTESTINAL: "HYPERMOTILITY, DIARRHEA" BLOOD: OTHER CHANGES	Annals of the New York Academy of Sciences. Vol. 89, Pg. 348, 1960.